Caladrius Biosciences to Participate at Upcoming September Conferences

Go Back
Sep 7, 2017

BASKING RIDGE, N.J. (September 7, 2017) – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that the Company’s leadership will participate at the following upcoming September conferences:

19th Annual Rodman & Renshaw Global Investment Conference

International Symposium on Clinical Application of CD34-Positive Cells for Cardiac, Cerebral, Vascular, Bone and Liver Regeneration

  • Date and Time: Saturday, September 9, 2017, 1:00 pm JST
  • Venue: Toranomon Hills Forum, Tokyo, Japan
  • Website:
  • Panel: CD34+ Cell Therapy for Ischemic Tissue Repair: Two Decades of Evidence
  • Panelist: Douglas W. Losordo, MD, Chief Medical Officer, Caladrius

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. For more information on Caladrius please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.



Primary Logo

Source: Caladrius Biosciences, Inc.